is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor
• in combination with fulvestrant in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor
• in combination with fulvestrant in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Treatment with IBRANCE should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor
• in combination with fulvestrant in women who have received prior endocrine therapy
• In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Treatment with IBRANCE should be initiated and supervised by a physician experienced in the use of anticancer medicinal products
Gastroesophageal Reflux Disease (GERD)
- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD)
In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and
- healing of Helicobacter pylori associated duodenal ulcer and
- prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
Patients requiring continued NSAID therapy
- healing of gastric ulcers associated with NSAID therapy.
- prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.
Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.
Treatment of Zollinger Ellison Syndrome
Adolescents from the age of 12 years
Gastroesophageal Reflux Disease (GERD)
- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD)
In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori
Gastroesophageal Reflux Disease (GERD)
- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD)
In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and
- healing of Helicobacter pylori associated duodenal ulcer and
- prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
Patients requiring continued NSAID therapy
- healing of gastric ulcers associated with NSAID therapy.
- prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.
Treatment of Zollinger Ellison Syndrome
Nexicure tablets are indicated in adolescents from the age of 12 years for:
Gastroesophageal Reflux Disease (GERD)
- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD)
In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori
Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Acute coronary syndrome:
Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
In adults, children, and toddlers aged 6 year and above:
For the relief of:
• Nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
• Symptoms of chronic idiopatic urticaria.
Fomicyt is indicated in all age groups for the treatment of the following infections when it is considered inappropriate to use antibacterial agents that are commonly recommended for their initial treatment:
- Complicated Urinary Tract Infections
- Infective Endocarditis
- Bone and Joint Infections
- Hospital-Acquired Pneumonia, Including Ventilator-Associated Pneumonia
- Complicated Skin and Soft Tissue Infection
- Bacterial Meningitis
- Complicated Intra-Abdominal Infections
- Bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
For adult patients with type 2 diabetes mellitus:
Glycimet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Glycimet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Glycimet is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.
Glycimet is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Antepartum
• Induction of labour for medical reasons, e.g. in cases of Rh problems, post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia)
• Stimulation of labour in hypotonic uterine inertia
• Early stages of pregnancy as adjunctive therapy for the management of incomplete, inevitable, or missed abortion.
Postpartum
• During caesarean section, but following delivery of the child
• Prevention and treatment of postpartum uterine atony and haemorrhage
